Advertisement

Prevalence of HFE (hemochromatosis gene) mutations in unselected male patients with type 2 diabetes

      Abstract

      To assess the prevalence of mutations in the HFE (hemochromatosis) gene in unselected male patients with type 2 diabetes, we examined 220 white men without known diabetes and 220 age-matched white men with type 2 diabetes for mutations in the HFE gene. Nucleotide 845 (C282Y) and 187(H63D) alleles were amplified by polymerase chain reaction (PCR) with lymphocyte DNA. The PCR products were analyzed by restriction enzyme digestion. One of the 220 patients (0.45%) with diabetes was homozygous for the HFE 845A (C282Y) mutation and 25 (11.3%) were heterozygous for the same mutation, of whom 3 (1.3%) were compound heterozygotes also carrying the HFE 187G (H63D) mutation. These frequencies did not differ significantly from the control population without diabetes. There is no evidence that HFE mutations are found in excess in unselected male patients with type 2 diabetes, and there is no indication for a population-based search for an excess of these alleles in type 2 diabetes. (J Lab Clin Med 2000;135:170-3)

      Abbreviations:

      HFE (hemochromatosis gene), HH (hereditary hemochromatosis), PCR (polymerase chain reaction), TIBC (total iron-binding capacity)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Edwards CQ
        • Kushner JP
        Screening for hemochromatosis.
        N Engl J Med. 1993; 328: 1616-1620
        • Merryweather-Clarke AT
        • Pointon JJ
        • Shearman JD
        • Robson KJH
        Global prevalence of putative hemochromatosis mutations.
        J Med Genet. 1997; 34: 275-278
        • Willis G
        • Wimperis JZ
        • Lonsdale R
        • Jennings BA
        hemochromatosis gene mutation in hepatocellular cancer.
        Lancet. 1997; 350: 565-566
        • Willis G
        • Jennings BA
        • Goodman E
        • Fellows IW
        • Wimperis JZ
        A high prevalence of HLA-H 845A mutations in hemochromatosis patients and the normal population in eastern England.
        Blood Cell Mol Dis. 1997; 23: 288-291
        • Gollan JL
        Diagnosis of hemochromatosis.
        Gastroenterology. 1983; 84: 418-421
        • Cotler SJ
        • Lin M
        • Carlson TH
        • Bronner MP
        • Labbe RF
        • Perkins JD
        • et al.
        Serum iron studies do not identify patients with end stage liver disease.
        Gastroenterology. 1996; 110: A1175
        • Rosner IA
        • Askari AD
        • McLaren GD
        • Muir A
        Arthropathy, hypouricemia and normal serum iron studies in hereditary hemochromatosis.
        Am J Med. 1981; 70: 870-874
        • Bassett ML
        • Halliday JW
        • Ferris RA
        • Powell LW
        Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests.
        Gastroenterology. 1984; 87: 628-633
        • Feder JN
        • Gnirke A
        • Thomas W
        • et al.
        A novel MHC class I-like gene is mutated in patients with hereditary hemochromatosis.
        Nat Genet. 1996; 13: 399-408
        • Turnbull AJ
        • Mitchison HC
        • Peaston RTP
        • Lai LC
        • Bennett MK
        • Taylor R
        • et al.
        The prevalence of hereditary hemochromatosis in a diabetic population.
        Q J Med. 1997; 90: 271-275
        • O'Brien T
        • Barrett B
        • Murray DM
        • Dineen S
        • O'Sullivan DJ.
        Usefulness of biochemical screening of diabetic patients for hemochromatosis.
        Diabetes Care. 1990; 13: 532-534
        • Singh BM
        • Grunewald RA
        • Press M
        • Muller BR
        • Wise PH
        Prevalence of hemochromatosis amongst patients with diabetes mellitus.
        Diabet Med. 1992; 9: 730-731
        • Moirand R
        • Adams PC
        • Bicheler V
        • Brissot P
        • Deugnier Y
        Clinical features of genetic hemochromatosis in women compared with men.
        Ann Intern Med. 1997; 127: 105-110
        • George DK
        • Evans RM
        • Crofton RW
        • Gunn IR
        Testing for hemochromatosis in the diabetic clinic.
        Ann Clin Biochem. 1995; 32: 521-526
        • Phelps G
        • Chapman I
        • Hall P
        • Braund W
        • Mackinnon M
        Prevalence of genetic hemochromatosis among diabetic patients [comment].
        Lancet. 1989; 2: 233-234
        • Balan V
        • Baldus W
        • Fairbanks V
        • Michels V
        • Burritt M
        • Klee G
        Screening for hemochromatosis: a cost-effectiveness study based on 12,258 patients.
        Gastroenterology. 1994; 107: 453-459
        • Conte D
        • Manachino D
        • Colli A
        • Guala A
        • Aimo G
        • Andreoletti M
        • et al.
        Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus.
        Ann Intern Med. 1998; 128: 370-373
        • Kaye TB
        • Guay AT
        • Simonson DC
        Non-insulin dependent diabetes mellitus and elevated serum ferritin level.
        J Diabetes Complications. 1993; 7: 246-249
        • Frayling T
        • Ellard S
        • Grove J
        • Walker M
        • Hattersley AT
        C282Y mutation in HFE (hemochromatosis) gene and type 2 diabetes.
        Lancet. 1998; 351: 1933-1934
        • Braun J
        • Donner H
        • Plock K
        • Rau H
        • Usadel KH
        • Badenhoop K
        Hereditary hemochromatosis mutations (HFE) in patients with type 2 diabetes mellitus.
        Diabetologia. 1998; 41: 983
        • Behn PS
        • Glaser B
        • Permutt A
        Contribution of the C282Y hereditary haemochromatosis mutation to type 2 diabetes mellitus in Ashkenazi Jews.
        Diabetes. 1998; 47: 1523
        • Rasmussen S
        • Echwald S
        • Hansen L
        • et al.
        Analysis of the relationship between a common Cys 282Tyr variant of the hereditary haemochromatosis gene and NIDDM.
        Diabetologia. 1997; 40: S1653
        • Kwan T
        • Leber B
        • Ahuja S
        • Carter R
        • Gerstein HC
        Patients with type 2 diabetes have a high frequency of the C282Y mutation of the haemochromatosis gene.
        Clin Invest Med. 1998; 21: 252-257
        • Fernandez-Real JM
        • Vendrell J
        • Baiget M
        • Gimferrer E
        • Ricart W
        C282Y and H63D mutations of the haemochromatosis candidate gene in type 2 diabetes.
        Diabetes Care. 1999; 22: 525
        • Dubois-Laforgue D
        • Caillat-Zucman S
        • Djilali-Saiah I
        • et al.
        Mutations in HFE, the haemochromatosis candidate gene, in patients with NIDDM.
        Diabetes Care. 1998; 21: 1371-1372
        • Inoue Y
        • Nakanishi K
        • Hiraga T
        • Okubo M
        • Murase T
        • Kosaka K
        • et al.
        Recovery of pancreatic beta-cell function in hemochromatosis: combined treatment with recombinant human erythropoietin and phlebotomy.
        Am J Med Sci. 1997; 314: 401-402
        • Frayling T
        • Ellard S
        • Ayres S
        • Ayres R
        • Hattersley AT
        Letter.
        Lancet. 1998; 352: 1068